Shanghai Leader Peptide Biotechnology Tesamorelin
As of 9 Aug 2026, Finnrick has published 9 independent lab tests of Tesamorelin from Shanghai Leader Peptide Biotechnology: 5 passed and 4 failed under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 4 Jun 2026. The current Finnrick rating for Shanghai Leader Peptide Biotechnology Tesamorelin is 50%.
Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.
Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.
| Date | Result | Certificate |
|---|---|---|
| 4 Jun 2026 | Pass | Certificate tpwqzp2 |
| 6 May 2026 | Pass | Certificate er4c54u |
| 23 Apr 2026 | Fail | Certificate 79pgrst |
| 13 Apr 2026 | Pass | Certificate qu6z5z3 |
| 29 Mar 2026 | Fail | Certificate 8h6ctb8 |
| 16 Mar 2026 | Fail | Certificate hrged9g |
| 2 Mar 2026 | Pass | Certificate pnmzktw |
| 20 Feb 2026 | Pass | Certificate y8r8tg2 |
| 29 Jan 2026 | Fail | Certificate 642wt78 |